2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH SUSAN HALABI
Racial Disparities in Prostate Cancer Treatment and Outcomes

VIEW ALL PROSTATE CANCER VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MICHAEL HOFMAN
Theranostic Approaches for Advanced Prostate Cancer

VIEW ALL IMAGING: PROSTATE VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL nmCRPC VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MATTHEW GALSKY
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Featured Videos

#AUA14 - Do cystine parameters predict clinical stone activity - Session Highlights

ORLANDO, FL USA (UroToday.com) - Litholink Corporation has recently developed a solid-phase assay, cystine capacity, that is thought to be a more reliable estimate of stone-forming potential than cystine concentration. To date, the recommended capacity target of > 150 mg/L has not been directly correlated with clinical stone recurrence.

auaTo investigate the relationship between urinary cystine capacity and clinical stone activity, the authors performed a prospective evaluation of 35 cystinuric patients. Stone activity (quiescent vs active) was correlated with cystine capacity during follow up. Stone activity was defined as an increase in size of existing stones, development of new stones, or passage or intervention for stones not previously seen on imaging. The values obtained for cystine capacity ranged from -470 mg/L to 193 mg/L. The highest cystine capacity value associated with a stone event was 126 mg/L. Of the patients who were able to achieve a capacity level > 100, the longest period of sustaining this level was 48 months, and this occurred in 2 patients. Cystine concentration was significantly lower for quiescent urine collections (236 ± 113 mg/L vs 322 ± 168 mg/L, p < 0.01), while cystine capacity was significantly greater for quiescent urines (62.8 ± 59.0 mg/L vs -22.8 ± 120.7 mg/L, p < 0.01), respectively, demonstrating that urinary cystine capacity is associated with clinical stone activity. ROC analysis performed for cystine capacity identified an area under the curve of 0.74. No patients formed stones with capacity > 126 mg/dl (specificity 100%) but 71% of urines with capacity < 126 mg/L had no stone activity (sensitivity 17.5%).

The results suggest the goal for capacity should be lower than previously stated, unfortunately few patients, however, demonstrated the ability to maintain a high level of capacity over time. Determination of a more clinically appropriate goal may prevent additional toxicity with higher doses of thiol-binding agents.

Presented by Justin I. Friedlander, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Dallas, TX USA

Written by Zhamshid Okhunov, MD, University of California (Irvine), and medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe